Laboratory of Molecular Nutrition, College of Food Science and Engineering, National Engineering Laboratory for Deep Processing of Rice and Byproducts, Central South University of Forestry and Technology, Changsha, Hunan 410004, China.
Food Funct. 2017 Nov 15;8(11):4028-4041. doi: 10.1039/c7fo00654c.
Hyperlipidemia occurs very often in modern society along with a high calorie intake and is regarded as one of the greatest risk factors for the prevalence of cardiac vascular disease (CVD). In this study, we investigated the anti-hyperlipidemic effect of the rice bran polysaccharides (RBP) and its mechanism in a high fat diet animal model. 60 ICR mice were randomly divided into 3 groups, which included Control, HFD (high fat diet) and HFD + RBP, and each group included 20 mice. The control group was fed with a standard diet while the other two groups were fed with HFD. In addition, the HFD + RBP group was fed with 500 mg kg of rice bran polysaccharides by intragastric administration while the other two groups were intragastrically administered with water. The results showed that RBP treatment for 10 weeks obviously decreased the body weight, liver weight and adipose tissues of mice; and it decreased the levels of total cholesterol (TC), triglycerides (TG) and low density lipoprotein-cholesterol (LDL-c) in the plasma. H&E staining of the liver tissues showed that RBP treatment decreased the size of fat droplets compared with the HFD group. Microarray analysis revealed that RBP treatment results in 80 genes being up-regulated while 72 genes were down-regulated in the tissues of liver. IPA software analysis suggested that NF-κB may play a vital role in the lipid-lowering effect of RBP. Real-time quantitative PCR confirmed that the mRNA levels of PPAR-α, PPAR-γ, PPAR-δ, SREBP-1C, FASN, ACC, SIRT and CD36, which are related to lipid metabolism, were significantly regulated by RBP supplementation compared to HFD. The western blot analysis further confirmed these altered expressions after RBP treatment. Taken together, these results suggest that the oral administration of RBP exerts lipid-lowering in high fat diet mice via regulating the lipid metabolism-related gene expression.
高脂血症在现代社会中经常发生,伴随着高热量摄入,被认为是心血管疾病(CVD)流行的最大危险因素之一。在本研究中,我们研究了米糠多糖(RBP)在高脂肪饮食动物模型中的抗高脂血症作用及其机制。将 60 只 ICR 小鼠随机分为 3 组,分别为对照组、HFD(高脂肪饮食)组和 HFD+RBP 组,每组 20 只。对照组喂食标准饮食,而另外两组喂食 HFD。此外,HFD+RBP 组通过灌胃给予 500mg/kg 的米糠多糖,而另外两组灌胃给予水。结果表明,RBP 治疗 10 周可明显降低小鼠的体重、肝重和脂肪组织;并降低血浆总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-c)水平。肝组织 H&E 染色显示,RBP 治疗组与 HFD 组相比,肝组织中的脂肪滴体积减小。微阵列分析显示,RBP 处理导致 80 个基因上调,72 个基因下调。IPA 软件分析表明,NF-κB 可能在 RBP 的降脂作用中发挥重要作用。实时定量 PCR 证实,与 HFD 相比,RBP 补充剂显著调节与脂质代谢相关的基因,如 PPAR-α、PPAR-γ、PPAR-δ、SREBP-1C、FASN、ACC、SIRT 和 CD36 的 mRNA 水平。Western blot 分析进一步证实了 RBP 处理后这些改变的表达。综上所述,这些结果表明,RBP 的口服给药通过调节脂质代谢相关基因的表达,在高脂肪饮食小鼠中发挥降脂作用。